摘要
目的:探讨柳氮磺吡啶肠溶片联合双歧杆菌活菌胶囊治疗溃疡性结肠炎的临床效果及对患者血清炎症因子水平的影响。方法:选取本院消化内科2016年9月-2018年5月收治的82例溃疡性结肠炎患者,根据入院先后顺序分为试验组和对照组,各41例。对照组给予柳氮磺吡啶肠溶片治疗,试验组在对照组的基础上给予双歧杆菌活菌胶囊治疗。连续治疗8周后,比较两组治疗效果、肠道菌群、血清炎症因子水平及T淋巴细胞亚群情况。结果:试验组治疗总有效率为92.68%明显高于对照组的75.61%(P<0.05)。治疗后,试验组双歧杆菌、肠球菌及乳酸菌数量均明显高于对照组(P<0.05),试验组肿瘤坏死因子-α(TNF-α)、IL-6、IL-8、C反应蛋白(CRP)及降钙素原(PCT)均明显低于对照组(P<0.05),试验组CD3^+、CD4^+及CD4^+/CD8^+均低于对照组,而CD8^+高于对照组(P<0.05)。结论:双歧杆菌活菌胶囊联合柳氮磺吡啶肠溶片治疗溃疡性结肠炎能有效提高治疗效果,降低炎症反应,改善免疫功能。
Objective:To investigate the clinical effect of Sulfasalazine Enteric-coated Tablets combined with Live Bifidobacterium Capsules in the treatment of ulcerative colitis and its effect on serum inflammatory factors.Method:A total of 82 patients with ulcerative colitis admitted to the department of gastroenterology in our hospital from September 2016 to May 2018 were selected,and they were divided into experimental group and control group according to the order of admission,41 cases in each group.The control group was treated with Sulfasalazine Enteric-coated Tablets,and the experimental group was treated with Live Bifidobacterium Capsules on the basis of the control group.After 8 weeks of continuous treatment,treatment effect,intestinal flora,serum inflammatory factors and T lymphocyte subsets of the two groups were compared.Result:The total effective rate in the experimental group was 92.68% significantly higher than 75.61% in the control group (P<0.05).After treatment,the number of Bifidobacteria,Enterococcus and Lactobacillus in the experimental group were significantly higher than those in the control group (P<0.05).Tumor necrosis factor-α (TNF-α),IL-6,IL-8,C-reactive protein (CRP) and procalcitonin (PCT) in the experimental group were significantly lower than those in the control group (P<0.05).After treatment,CD3^+,CD4^+ and CD4^+/CD8^+ in the experimental group were lower than those in the control group,while CD8^+ was higher than that in the control group (P<0.05).Conclusion:Live Bifidobacterium Capsules combined with Sulfasalazine Enteric-coated Tablets can effectively improve the treatment effect of ulcerative colitis,reduce inflammation and improve immune function.
作者
李水康
李振飞
LI Shuikang;LI Zhenfei(Wuchuan People’s Hospital,Wuchuan 524500,China)
出处
《中国医学创新》
CAS
2020年第4期20-23,共4页
Medical Innovation of China
关键词
双歧杆菌活菌胶囊
柳氮磺吡啶肠溶片
溃疡性结肠炎
血清炎症因子
Live Bifidobacterium Capsules
Sulfasalazine Enteric-coated Tablets
Ulcerative colitis
Serum inflammatory factor
